Candel Therapeutics (CADL) Stock Forecast & Price Target

Compare

398 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CADL Analyst Ratings

Strong Buy

5 Buy

1 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Candel

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CADL Stock 12 Month Forecast

Average Price Target

$18.33

▲(296.75% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Candel Therapeutics in the last 3 months. The average price target is $18.33 with a high forecast of $25.00 and a low forecast of $7.00. The average price target represents a 296.75% change from the last price of $4.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","8.75":"$8.75","14.5":"$14.5","20.25":"$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8.75,14.5,20.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.889230769230769,8.39846153846154,9.907692307692308,11.416923076923077,12.926153846153847,14.435384615384617,15.944615384615386,17.453846153846154,18.963076923076922,20.472307692307695,21.981538461538463,23.49076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,6.376153846153846,7.372307692307692,8.368461538461538,9.364615384615384,10.360769230769229,11.356923076923076,12.353076923076923,13.349230769230768,14.345384615384614,15.341538461538459,16.337692307692308,17.333846153846153,{"y":18.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.38,5.504615384615384,5.6292307692307695,5.753846153846154,5.878461538461538,6.003076923076923,6.127692307692308,6.252307692307692,6.376923076923077,6.501538461538462,6.626153846153846,6.750769230769231,6.875384615384616,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.28,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.89,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$18.33

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

397.84%

Upside

Reiterated

11/14/25

Candel Therapeutics (CADL) Receives a Buy from H.C. Wainwright

Yigal Nochomovitz

Citi

$25→$24

Buy

419.48%

Upside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: TELA Bio (NASDAQ: TELA), Candel Therapeutics (NASDAQ: CADL) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Alec Stranahan

Bank of America Securities

Hold

51.52%

Upside

Reiterated

11/14/25

Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)

John Newman

Canaccord Genuity

$25

Buy

441.13%

Upside

Reiterated

11/14/25

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

Oliver McCammon

LifeSci Capital

$16

Buy

246.32%

Upside

Reiterated

11/13/25

Analysts' Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)Today, Candel (Nasdaq: CADL) reported Q3 earnings and provided a corporate update. As a reminder, Candel’s lead program, called CAN- 2409, is a locally-administered, replicaon-de fecv e adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to paen ts’ tumors. Last month, we inia ted coverage on Candel (inia on r eport HERE), where our focus was (and connues t o be) on the role that CAN-2409 may play in the treatment landscape for intermediate- to high-risk localized prostate cancer paen ts.

Sudan Loganathan

Stephens

$15

Buy

224.68%

Upside

Initiated

10/28/25

Candel initiated with an Overweight at Stephens on differentiated pipelineCandel initiated with an Overweight at Stephens on differentiated pipeline

Ilya Zubkov

Freedom Capital Markets

$13

Buy

181.39%

Upside

Initiated

07/14/25

Candel Therapeutics (CADL) Has a New Rating from Freedom Capital Markets

Kemp Dolliver

Brookline Capital Markets

$25

Buy

441.13%

Upside

Initiated

07/09/25

Candel Therapeutics initiated with a Buy at BrooklineCandel Therapeutics initiated with a Buy at Brookline

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. Maldonado

H.C. Wainwright

$23

Buy

397.84%

Upside

Reiterated

11/14/25

Candel Therapeutics (CADL) Receives a Buy from H.C. Wainwright

Yigal Nochomovitz

Citi

$25→$24

Buy

419.48%

Upside

Reiterated

11/14/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: TELA Bio (NASDAQ: TELA), Candel Therapeutics (NASDAQ: CADL) and Acrivon Therapeutics, Inc. (NASDAQ: ACRV)

Alec Stranahan

Bank of America Securities

Hold

51.52%

Upside

Reiterated

11/14/25

Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)

John Newman

Canaccord Genuity

$25

Buy

441.13%

Upside

Reiterated

11/14/25

Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)

Oliver McCammon

LifeSci Capital

$16

Buy

246.32%

Upside

Reiterated

11/13/25

Sudan Loganathan

Stephens

$15

Buy

224.68%

Upside

Initiated

10/28/25

Candel initiated with an Overweight at Stephens on differentiated pipelineCandel initiated with an Overweight at Stephens on differentiated pipeline

Ilya Zubkov

Freedom Capital Markets

$13

Buy

181.39%

Upside

Initiated

07/14/25

Candel Therapeutics (CADL) Has a New Rating from Freedom Capital Markets

Kemp Dolliver

Brookline Capital Markets

$25

Buy

441.13%

Upside

Initiated

07/09/25

Candel Therapeutics initiated with a Buy at BrooklineCandel Therapeutics initiated with a Buy at Brookline

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Candel Therapeutics

1 Month

xxx

Success Rate

2/5 ratings generated profit

Average Return

+0.84%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +0.84% per trade.

3 Months

xxx

Success Rate

1/5 ratings generated profit

Average Return

-11.42%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -11.42% per trade.

1 Year

Andres Y. MaldonadoH.C. Wainwright

Success Rate

0/5 ratings generated profit

Average Return

-14.82%

reiterated a buy rating 16 days ago

Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.82% per trade.

2 Years

xxx

Success Rate

0/5 ratings generated profit

Average Return

-14.82%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -14.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CADL Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CADL has received 12 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CADL average Analyst price target in the past 3 months is 18.33.

Each month's total comprises the sum of three months' worth of ratings.

CADL Financial Forecast

CADL Earnings Forecast

Next quarter’s earnings estimate for CADL is -$0.25 with a range of -$0.26 to -$0.23. The previous quarter’s EPS was -$0.21. CADL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CADL has Performed in-line its overall industry.

CADL Sales Forecast

Next quarter’s sales forecast for CADL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CADL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CADL has Performed in-line its overall industry.

CADL Stock Forecast FAQ

What is CADL’s average 12-month price target, according to analysts?

Based on analyst ratings, Candel Therapeutics’s 12-month average price target is 18.33.

What is CADL’s upside potential, based on the analysts’ average price target?

Candel Therapeutics has 296.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CADL a Buy, Sell or Hold?

Candel Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.

What is Candel Therapeutics’s price target?

The average price target for Candel Therapeutics is 18.33. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 296.75% Increase from the current price of $4.62.

What do analysts say about Candel Therapeutics?

Candel Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of CADL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Candel Therapeutics (CADL) Stock Forecast & Price Target

CADL Analyst Ratings

CADL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Candel Therapeutics

CADL Analyst Recommendation Trends

CADL Financial Forecast

CADL Earnings Forecast

CADL Sales Forecast

CADL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts